Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at 6-month angiographic follow-up.
OBJECTIVE
Patients with diabetes mellitus (DM) are at high risk for restenosis after coronary stenting. However, whether drug-eluting stents are effective in diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI) is uncertain. We report on a series of patients with or without DM followed up for 6 months after sirolimus-eluting stent implantation.


METHODS
This cohort study enrolled 195 STEMI patients who underwent sirolimus-eluting stent implantation and accepted angiographic followup at 6 months.


RESULTS
There were no significant differences between the two groups in baseline clinical characteristics and risk factors. The two groups were treated with similar stent lengths and diameters. The unadjusted in-stent restenosis was significantly higher in diabetic than in non-diabetic patients at 6 months (7.8 vs. 1.7, P < 0.05). Multivariate analysis showed that only diabetes and current smoking were independent predictors of restenosis (odds ratio 12.82 and 7.98, respectively, both P < 0.05).


CONCLUSIONS
The present study demonstrated that diabetes increased restenosis after sirolimus-eluting stent placement in STEMI patients. This finding implicates that diabetes remains an important predictor for restenosis in the DES era.
Department of Cardiology, General Hospital of PLA Chengdu Military Area Command, Chengdu, Sichuan, People's Republic of China.
Shuangtao
S
Ma
Dachun
D
Yang
Xin
X
Zhang
Bing
B
Tang
De
D
Li
Meiqin
M
Sun
Yongjian
Y
Yang
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015331:Cohort Studies; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy; D023903:Coronary Restenosis / Q000000981:diagnostic imaging* / Q000209:etiology / Q000628:therapy; D048909:Diabetes Complications / Q000000981:diagnostic imaging* / Q000628:therapy; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D012907:Smoking / Q000009:adverse effects; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D020123:Sirolimus